JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer
Open Access
- 4 December 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (49), 19226-19231
- https://doi.org/10.1073/pnas.0700735104
Abstract
Histone methylation is a dynamic process that participates in a diverse array of cellular processes and has been found to associate with cancer. Recently, several histone demethylases have been identified that catalyze the removal of methylation from histone H3 lysine residues. Through bioinformatic and biochemical analysis, we identified JARID1B as a H3K4 demethylase. Overexpression of JARID1B resulted in loss of tri-, di-, and monomethyl H3K4 but did not affect other histone lysine methylations. In vitro biochemical experiments demonstrated that JARID1B directly catalyzes the demethylation. The enzymatic activity requires the JmjC domain and uses Fe(II) and α-ketoglutarate as cofactors. Furthermore, we found that JARID1B is up-regulated in prostate cancer tissues, compared with benign prostate samples. We also demonstrated that JARID1B associates with androgen receptor and regulates its transcriptional activity. Thus, we identified JARID1B as a demethylase capable of removing three methyl groups from histone H3 lysine 4 and up-regulated in prostate cancer.Keywords
This publication has 37 references indexed in Scilit:
- Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificityNature, 2007
- Opposing LSD1 complexes function in developmental gene activation and repression programmesNature, 2007
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004
- Gene expression profiling identifies clinically relevant subtypes of prostate cancerProceedings of the National Academy of Sciences, 2004
- ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining PlatformNeoplasia, 2004
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002
- Retinoblastoma-binding Protein 2 (Rbp2) Potentiates Nuclear Hormone Receptor-mediated TranscriptionJournal of Biological Chemistry, 2001
- A Novel Gene (PLU-1) Containing Highly Conserved Putative DNA/Chromatin Binding Motifs Is Specifically Up-regulated in Breast CancerJournal of Biological Chemistry, 1999
- Characterization of the retinoblastoma binding proteins RBP1 and RBP2.1993